Cue Health Collaborates With Google Cloud To Add Variant Sequencing, Tracking And Prediction Capabilities To Its Cue Platform

Posted: October 6, 2021 at 9:15 a.m. EDT|Update: 1 hour ago

SAN DIEGO, October 6, 2021 / PRNewswire / – Cue Health Inc. (Nasdaq: HLTH), a mission-driven healthcare technology company, today introduced its new collaboration with Google Cloud to address the country’s critical need for real-time respiratory viral variant sequencing and tracking . The new capabilities will be incorporated into the Cue Integrated Care Platform, which includes the Cue Health Monitoring System and the first of its kind COVID-19 molecular test – cleared by the FDA for home and over-the-counter use. , with precise results transmitted to mobile devices in about 20 minutes. Cue Health aims to harness the power of artificial intelligence (AI), machine learning (ML), analytics, and cutting-edge privacy and security tools from Google Cloud to improve and evolve the platform. form of Cue Health for the benefit of all stakeholders in the ongoing fight against this pandemic and future ones.

(PRNewsfoto / Cue Health Inc.)

By integrating cloud-connected COVID-19 information with sequencing data and AI tools, Cue Health and Google Cloud will provide public health officials and researchers with critical, real-time information on the types of variants – including including their geographic distribution – and predictive capabilities to help identify and curb emerging threats. Cue Health’s Google Cloud-enabled infrastructure and built-in sequencing capabilities are intended to be a useful tool not only in the fight against COVID-19, but also in mitigating future outbreaks of other infectious diseases, such as influenza. and respiratory syncytial virus (RSV), areas in which Cue Health is currently developing future test offerings.

“At Cue, we aim to provide people with access to their health information through an easy-to-use, portable, connected and fast platform,” said Ayub Khattak, CEO and co-founder of Cue Health. “Through our relationships with the Ministries of Defense and Health and Human Services, we are already making an impact in many states, where it has been extremely rewarding to see Cue helping to make health information accessible and timely. . With Google Cloud, we can combine immediate, connected lab-quality diagnostics with the power of genome sequencing and AI-enabled predictive capabilities to develop a new kind of tool for public health. “

“Cue Health is a pioneering critical technology that has already had a huge impact in the fight against COVID-19,” said Janet Kennedy, Vice President, North America Regions, Google Cloud. “Through this collaboration, we bring Google Cloud’s expertise in data analytics, AI and ML to Cue, helping them reach even more communities and have even greater impact by helping to identify, predict and mitigate the spread of infectious diseases. “

Thanks to its suite of innovative products and security solutions, Google Cloud tools are already enabling Cue Health to deliver its COVID-19 tests to communities across the country. Cue Health’s COVID-19 test has been deployed to thousands of schools, protecting not only students, faculty, and staff, but family and community members as well.

“Families are thrilled when the Cue Health test can be done in school and their children don’t need an extended absence while waiting for traditional lab test results. It really is a win, a win. for everyone. We hope to expand testing in our district in the near future because the health cue monitoring system is so simple and convenient, ”said Lori Schneider, director of nursing services at the Fairbanks, Alaska North Star Borough School District.

Cue Health’s COVID-19 tests are also used daily in a variety of other settings where a highly accurate and uncompromising testing solution is required, from nursing homes and correctional facilities to hospitals, community health clinics and to world-class organizations.

About Cue Health
Cue Health (Nasdaq: HLTH) is a mission-driven health technology company that puts consumers in control of their health information and puts diagnostic information at the center of care. Cue Health empowers people to manage their health with real-time, actionable, and connected health information, giving individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, no whenever, in a device that fits in the palm of your hand. Cue Health’s first COVID-19 test was the first molecular diagnostic test cleared by the FDA for home and over-the-counter use without physician supervision. Outside United States, Cue Health has received the CE Mark in the European Union, Interim Prescription Authorization from Health Canada and regulatory approval from india Central organization for the control of pharmaceutical standards. Cue Health was founded in 2010 and is headquartered in San Diego. For more information, please visit

About the Cue Health Platform
The Cue Health platform combines the hardware of the Cue health monitoring system and the chemistry of the Cue Health test cartridges with cloud-based analytics and security to run and report high-quality diagnostic tests for people in minutes, anywhere via the Cue Health mobile app. The Cue Health platform has been designed so that it can be directly integrated into existing workflows and on-demand services, such as telemedicine, e-prescribing services and electronic medical records or EMR systems.

Forward-looking statements
Statements in this press release regarding future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements”. The words, without limitation, “anticipate”, “believe”, “continue”, “could”, “estimate”, “‘wait”, “project”, “should”, “target”, “will”, “Would” and similar phrases are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those shown in these forward-looking statements due to various important factors, including those relating to the expected capabilities of the Cue Health platform, the benefits that may be derived from Cue Health’s collaboration with Google Cloud, and the factors discussed in the “Risk Factors” section of the dated prospectus September 23, 2021 filed by Cue Health with the SEC. All forward-looking statements contained in this press release are based on the current expectations of Cue’s management team and speak only as of the date hereof, and Cue specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This product has not been authorized or approved by the FDA; but has been cleared by the FDA under an Emergency Use Clearance, or EUA. This product has only been authorized for the detection of SARS-CoV-2 nucleic acid, not for other viruses or pathogens. Emergency use of this product is only permitted for the duration of the declaration that there are circumstances that justify the authorization of emergency use of in vitro diagnostics for the detection and / or diagnosis of COVID -19 under Section 564 (b) (1) of the Federal Law. Food, Drug and Cosmetic Act, 21 USC § 360bbb-3 (b) (1), unless the statement is terminated or the authorization is earlier revoked.

View original content to download multimedia:

SOURCE Cue Santé Inc.

The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.

Source link

About Yvonne Lozier

Check Also

Benefits of e-invoicing software for law firms and lawyers

Wednesday, November 17, 2021 Running a law firm and performing administrative tasks requires a lot …

Leave a Reply

Your email address will not be published. Required fields are marked *